Oct 2026
SGLT2 Inhibitor Therapy and Risk of Incident Atrial Fibrillation in Patients With HFpEF and Type 2 Diabetes.
Background Atrial fibrillation (AF) frequently coexists with Heart Failure with Preserved Ejection Fraction, particularly in patients with Type 2 Diabetes, due to shared cardiometabolic and inflammatory mechanisms. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiovascular benefit in HFpEF, but...
I. Acheampong, G. Blankson, Dennis D. Kumi et al.
· The Cardiology · 0 citations